It is recommended to use either targeted therapy alone or in combination with Programmed Death Receptor-1 (PD-1/PD-L1) immune checkpoint inhibitors as the first-line treatment or alternative therapy for advanced HCC (19–23). The gene discussed is CD274; the disease is hepatocellular carcinoma.